Back to News
Market Impact: 0.25
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial
Source: marketbeat.com
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Nektar Therapeutics presented new clinical and biomarker data for rezpegaldesleukin (REZPEG) at the EADV 2026 Congress. The update included six-month off-treatment results in severe-to-very-severe alopecia areata and molecular findings from its Phase IIb atopic dermatitis program, supporting continued clinical development but providing no numerical efficacy data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
NKTR0.55
More News
- Broadcom to lend Anthropic up to $42 billion to lease its chips, filing says
- Nike Warns Sales Slump Will Worsen This Fiscal Year
- $8.2B acquisition validates AI-picked chip stock: +20% since June
- Nuveen CEO on Schroders Deal, Plans for Combined Company
- New Mexico wants Meta to pay up to $40 billion in penalties after data privacy trial
- Markets slip on dollar pressure, but this IT stock is up 10% today